DrugMonitor™ Anti-Dinutuximab Antibody (VS-1224-YC361) (CAT#: VS-1224-YC361)

Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody targeting GD2, used in immunotherapy strategies to treat neuroblastoma and prevent relapse. The DrugMonitor™ Anti-Dinutuximab Antibody (VS-1224-YC361) is an anti-drug antibody (ADA) against Dinutuximab. This drug-based antibody is raised in mice immunized with the Dinutuximab. The anti-Dinutuximab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Dinutuximab in samples.

Specific Inquiry
  • Size:
  • Conjugation:
  • Purity:
  • Datasheet
  • MSDS
  • COA

Specifications

  • Host Animal
  • Mouse
  • Specificity
  • Dinutuximab
  • Target
  • Dinutuximab
  • Immunogen
  • Dinutuximab
  • Type
  • Mouse IgG
  • Species Reactivity
  • Human
  • Purity
  • >95%
  • Purification
  • Protein G
  • Applications
  • ELISA, PK/PD, ADA control
  • Format
  • Liquid
  • Concentration
  • Batch-dependent
  • Buffer
  • PBS, pH 7.4
  • Preservative
  • No preservatives
  • Storage
  • Store at 4°C for 1-2 weeks and at -20°C for 1 year. Avoid repeated freezing and thawing.
  • Generic name
  • Dinutuximab
  • Drug Weight
  • 145000.0 Da
  • Formula
  • C₆₄₂₂H₉₉₈₂N₁₇₂₂O₂₀₀₈S₄₈
  • Related Disease
  • neuroblastoma and prevent relapse

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Dinutuximab"

Afuco™ Anti-GD2 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-731)
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant chimeric (human/Mouse) antibody expressed in CHO binding to human GD2. It is a chimeric monoclonal antibody that induces antibody dependent cell-mediated cytotoxicity. It is intended as maintenance therapy (targeting minimal residual disease) for high risk neuroblastoma, administered after induction therapy, autologous stem cell transplantation and/or radiotherapy.

Customer Reviews and Q&As

Submit a review or a question

There are currently no Customer reviews or questions for VS-1224-YC361. Click the button above to contact us or submit your feedback about this product.

Popular products with customers


For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare